Fig. 7: Rapamycin treatment attenuates motor disability and neurological lesions in Ubap1 cKO mouse models.

a Schematic diagram of experimental procedures for rapamycin (Rap) treatment and behavioral testing in Ubap1 Syn-cKO mice. b Representative images of the indicated scores and quantification of hind limb clasping scores of mice with/without rapamycin treatment. Scale bar: 1 cm. WT Rap n = 10, Syn-cKO Veh n = 9, Syn-cKO Rap n = 8 mice. c The foot base angle analysis of mice with/without rapamycin treatment. WT Rap n = 12, Syn-cKO Veh n = 7, Syn-cKO Rap n = 6 mice. d Quantification of the time in 12 mm balance beam walking test from mice with/without rapamycin treatment. WT Rap n = 10, Syn-cKO Veh n = 6, Syn-cKO Rap n = 6 mice. e Representative sagittal sections from more than three mice per group showed enlarged ventricles and neurological lesions can be rescued by rapamycin treatment. Scale bar: 500 μm. f Representative images from more than three mice per group showed increased neuronal apoptosis by CC3 staining in vehicle-treated Syn-cKO mice and a robust attenuation in rapamycin-treated Syn-cKO mice. Scale bar: 100 μm. g Representative images from more than three mice per group showed activation of glia by Iba1 and GFAP staining in vehicle-treated Syn-cKO mice and a robust attenuation in rapamycin-treated Syn-cKO mice. Scale bar: 50 μm. All data represent the mean ± SEM; One-way ANOVA followed by Tukey’s multiple comparisons test (b–d), *p < 0.05, **p < 0.01, ^#p < 0.0001. Exact p-values and test statistics are provided as a Source Data file.